| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 18 | 2022 | 442 | 5.480 |
Why?
|
| Colorectal Neoplasms | 39 | 2024 | 616 | 4.540 |
Why?
|
| Early Detection of Cancer | 32 | 2025 | 513 | 4.000 |
Why?
|
| Colonoscopy | 20 | 2024 | 253 | 2.500 |
Why?
|
| Survivors | 6 | 2018 | 158 | 2.420 |
Why?
|
| Breast Neoplasms | 22 | 2020 | 956 | 2.240 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2018 | 247 | 2.110 |
Why?
|
| Mass Screening | 20 | 2024 | 667 | 1.930 |
Why?
|
| Humans | 96 | 2025 | 17707 | 1.900 |
Why?
|
| Aged | 66 | 2025 | 6150 | 1.850 |
Why?
|
| Middle Aged | 63 | 2025 | 7976 | 1.570 |
Why?
|
| Electronic Health Records | 7 | 2023 | 694 | 1.520 |
Why?
|
| Occult Blood | 13 | 2024 | 154 | 1.510 |
Why?
|
| Female | 73 | 2025 | 12729 | 1.460 |
Why?
|
| Algorithms | 5 | 2020 | 237 | 1.450 |
Why?
|
| Cancer Survivors | 3 | 2022 | 91 | 1.390 |
Why?
|
| Health Services Research | 4 | 2016 | 213 | 1.320 |
Why?
|
| Adaptation, Psychological | 4 | 2018 | 79 | 1.260 |
Why?
|
| Guideline Adherence | 4 | 2025 | 155 | 1.120 |
Why?
|
| Male | 45 | 2024 | 10094 | 1.070 |
Why?
|
| Animal Assisted Therapy | 2 | 2017 | 5 | 1.060 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 1927 | 1.050 |
Why?
|
| Child, Hospitalized | 2 | 2017 | 14 | 1.050 |
Why?
|
| Washington | 17 | 2020 | 382 | 1.010 |
Why?
|
| Antidepressive Agents | 3 | 2015 | 153 | 0.990 |
Why?
|
| Adenoma | 7 | 2024 | 94 | 0.950 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2025 | 125 | 0.900 |
Why?
|
| Practice Guidelines as Topic | 7 | 2025 | 314 | 0.880 |
Why?
|
| Risk Factors | 19 | 2023 | 3367 | 0.880 |
Why?
|
| United States | 19 | 2024 | 3914 | 0.860 |
Why?
|
| Comparative Effectiveness Research | 3 | 2013 | 66 | 0.820 |
Why?
|
| Postmenopause | 7 | 2009 | 243 | 0.810 |
Why?
|
| Epidemiologic Methods | 2 | 2012 | 80 | 0.780 |
Why?
|
| Adult | 25 | 2025 | 7658 | 0.780 |
Why?
|
| Bias | 4 | 2022 | 103 | 0.750 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 483 | 0.730 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 158 | 0.710 |
Why?
|
| Neoplasms, Second Primary | 4 | 2018 | 29 | 0.700 |
Why?
|
| Delivery of Health Care, Integrated | 8 | 2017 | 531 | 0.680 |
Why?
|
| Quality of Life | 4 | 2018 | 521 | 0.680 |
Why?
|
| Return to Work | 1 | 2019 | 2 | 0.660 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2019 | 6 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 387 | 0.650 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 1218 | 0.640 |
Why?
|
| Surveys and Questionnaires | 8 | 2019 | 1322 | 0.630 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 173 | 0.630 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 710 | 0.630 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 55 | 0.620 |
Why?
|
| Age Factors | 5 | 2024 | 918 | 0.590 |
Why?
|
| Papillomavirus Infections | 3 | 2025 | 139 | 0.570 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 35 | 0.560 |
Why?
|
| Sensitivity and Specificity | 6 | 2022 | 304 | 0.560 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 26 | 0.560 |
Why?
|
| Health Expenditures | 1 | 2018 | 70 | 0.550 |
Why?
|
| Time Factors | 6 | 2019 | 1095 | 0.550 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 40 | 0.540 |
Why?
|
| Cohort Studies | 14 | 2025 | 2589 | 0.530 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 13 | 0.520 |
Why?
|
| Feces | 2 | 2016 | 80 | 0.520 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 204 | 0.510 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 371 | 0.510 |
Why?
|
| Oncology Service, Hospital | 1 | 2015 | 1 | 0.510 |
Why?
|
| Bonding, Human-Pet | 1 | 2015 | 2 | 0.510 |
Why?
|
| Employment | 1 | 2016 | 44 | 0.510 |
Why?
|
| Endometrial Neoplasms | 2 | 2007 | 35 | 0.500 |
Why?
|
| Colonic Polyps | 3 | 2023 | 35 | 0.500 |
Why?
|
| Research | 2 | 2013 | 64 | 0.500 |
Why?
|
| Paroxetine | 1 | 2015 | 23 | 0.500 |
Why?
|
| Mammography | 3 | 2015 | 168 | 0.500 |
Why?
|
| Aspirin | 1 | 2016 | 63 | 0.500 |
Why?
|
| Population Surveillance | 1 | 2017 | 265 | 0.500 |
Why?
|
| Primary Prevention | 1 | 2016 | 70 | 0.500 |
Why?
|
| Insurance Coverage | 1 | 2016 | 105 | 0.490 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2025 | 8 | 0.480 |
Why?
|
| Psychometrics | 1 | 2015 | 122 | 0.470 |
Why?
|
| Insurance, Health | 1 | 2016 | 175 | 0.470 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2013 | 9 | 0.470 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 324 | 0.460 |
Why?
|
| Retrospective Studies | 13 | 2023 | 2471 | 0.460 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2012 | 53 | 0.450 |
Why?
|
| Professional Role | 1 | 2013 | 10 | 0.440 |
Why?
|
| Delivery of Health Care | 6 | 2022 | 397 | 0.440 |
Why?
|
| Epidemiologic Studies | 1 | 2013 | 29 | 0.430 |
Why?
|
| Medical Oncology | 1 | 2013 | 32 | 0.430 |
Why?
|
| Depressive Disorder | 1 | 2015 | 220 | 0.430 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 596 | 0.420 |
Why?
|
| Preventive Medicine | 1 | 2013 | 24 | 0.410 |
Why?
|
| Behavioral Sciences | 1 | 2012 | 2 | 0.410 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 131 | 0.410 |
Why?
|
| Health Personnel | 1 | 2013 | 123 | 0.400 |
Why?
|
| Reminder Systems | 5 | 2017 | 80 | 0.400 |
Why?
|
| Health Status Indicators | 1 | 2012 | 63 | 0.390 |
Why?
|
| Heart Diseases | 1 | 2012 | 75 | 0.380 |
Why?
|
| Health Policy | 1 | 2012 | 118 | 0.380 |
Why?
|
| Logistic Models | 6 | 2018 | 918 | 0.350 |
Why?
|
| Registries | 6 | 2019 | 470 | 0.350 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2011 | 71 | 0.350 |
Why?
|
| Databases, Factual | 1 | 2011 | 311 | 0.340 |
Why?
|
| Animals | 3 | 2017 | 262 | 0.340 |
Why?
|
| Postal Service | 5 | 2019 | 73 | 0.330 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 151 | 0.330 |
Why?
|
| Exercise | 4 | 2007 | 496 | 0.320 |
Why?
|
| Histamine H2 Antagonists | 1 | 2009 | 13 | 0.320 |
Why?
|
| Young Adult | 10 | 2025 | 2450 | 0.320 |
Why?
|
| Disease Progression | 3 | 2016 | 266 | 0.320 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 24 | 0.310 |
Why?
|
| Case-Control Studies | 8 | 2023 | 1117 | 0.310 |
Why?
|
| Patient Compliance | 4 | 2017 | 299 | 0.310 |
Why?
|
| Health Care Costs | 1 | 2010 | 222 | 0.300 |
Why?
|
| Breast | 1 | 2009 | 85 | 0.300 |
Why?
|
| Estrogens | 2 | 2007 | 61 | 0.290 |
Why?
|
| Research Design | 5 | 2013 | 372 | 0.290 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 355 | 0.280 |
Why?
|
| Progestins | 1 | 2007 | 25 | 0.280 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 99 | 0.270 |
Why?
|
| Colposcopy | 2 | 2023 | 4 | 0.270 |
Why?
|
| Dogs | 2 | 2017 | 17 | 0.270 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 260 | 0.270 |
Why?
|
| Thinness | 1 | 2006 | 32 | 0.260 |
Why?
|
| Odds Ratio | 6 | 2019 | 670 | 0.260 |
Why?
|
| Bone Density | 1 | 2006 | 97 | 0.250 |
Why?
|
| Hospitals, Pediatric | 2 | 2017 | 78 | 0.250 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 331 | 0.250 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 243 | 0.250 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 64 | 0.240 |
Why?
|
| Adolescent | 6 | 2019 | 3671 | 0.240 |
Why?
|
| Anxiety | 2 | 2018 | 152 | 0.230 |
Why?
|
| Patient Navigation | 2 | 2015 | 15 | 0.230 |
Why?
|
| SEER Program | 5 | 2020 | 92 | 0.230 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2004 | 3 | 0.230 |
Why?
|
| Estradiol | 1 | 2004 | 24 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2019 | 1106 | 0.230 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2004 | 23 | 0.230 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 194 | 0.210 |
Why?
|
| Vaginal Smears | 4 | 2025 | 48 | 0.210 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 144 | 0.210 |
Why?
|
| Survival Rate | 2 | 2013 | 262 | 0.200 |
Why?
|
| Primary Health Care | 3 | 2022 | 756 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1322 | 0.200 |
Why?
|
| Reproductive History | 2 | 2017 | 17 | 0.190 |
Why?
|
| Tamoxifen | 2 | 2018 | 56 | 0.170 |
Why?
|
| Intestinal Polyps | 1 | 2020 | 7 | 0.170 |
Why?
|
| Patient Selection | 2 | 2012 | 190 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 262 | 0.170 |
Why?
|
| Interviews as Topic | 2 | 2013 | 301 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2019 | 6 | 0.160 |
Why?
|
| Child | 2 | 2017 | 2481 | 0.160 |
Why?
|
| Linear Models | 3 | 2011 | 229 | 0.160 |
Why?
|
| Papillomaviridae | 3 | 2025 | 58 | 0.160 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 626 | 0.160 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2018 | 1 | 0.160 |
Why?
|
| Educational Status | 1 | 2019 | 198 | 0.160 |
Why?
|
| Motivation | 1 | 2019 | 130 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 179 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2018 | 113 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 203 | 0.140 |
Why?
|
| Pediatric Nursing | 1 | 2017 | 3 | 0.140 |
Why?
|
| Incidence | 2 | 2016 | 1269 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2017 | 36 | 0.140 |
Why?
|
| Nurses | 2 | 2015 | 35 | 0.140 |
Why?
|
| Comorbidity | 2 | 2016 | 590 | 0.140 |
Why?
|
| Contraceptives, Oral | 1 | 2017 | 26 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 16 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 243 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2017 | 215 | 0.130 |
Why?
|
| Overweight | 3 | 2007 | 270 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2016 | 20 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 159 | 0.130 |
Why?
|
| Risk | 2 | 2015 | 517 | 0.120 |
Why?
|
| Medical Records | 1 | 2015 | 97 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 260 | 0.120 |
Why?
|
| Inpatients | 1 | 2015 | 81 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 271 | 0.120 |
Why?
|
| Outpatients | 1 | 2015 | 107 | 0.120 |
Why?
|
| Prognosis | 3 | 2015 | 613 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2014 | 68 | 0.110 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 24 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 2013 | 13 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 10 | 0.110 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 123 | 0.110 |
Why?
|
| Utilization Review | 1 | 2013 | 48 | 0.110 |
Why?
|
| Observer Variation | 1 | 2013 | 37 | 0.110 |
Why?
|
| Selection Bias | 1 | 2013 | 18 | 0.110 |
Why?
|
| Observation | 1 | 2013 | 22 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2013 | 53 | 0.110 |
Why?
|
| Health Promotion | 1 | 2016 | 280 | 0.110 |
Why?
|
| Confidence Intervals | 3 | 2013 | 237 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2013 | 74 | 0.110 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2013 | 86 | 0.110 |
Why?
|
| Counseling | 1 | 2015 | 187 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2013 | 24 | 0.110 |
Why?
|
| Continuity of Patient Care | 2 | 2011 | 103 | 0.100 |
Why?
|
| Patient Preference | 1 | 2013 | 48 | 0.100 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 8 | 0.100 |
Why?
|
| Recurrence | 1 | 2013 | 189 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 216 | 0.100 |
Why?
|
| Hypertension | 1 | 2017 | 498 | 0.100 |
Why?
|
| Translational Medical Research | 1 | 2012 | 34 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2012 | 9 | 0.100 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 102 | 0.100 |
Why?
|
| Genetic Counseling | 1 | 2012 | 28 | 0.100 |
Why?
|
| Clinical Coding | 1 | 2011 | 11 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2012 | 222 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 100 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 137 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 50 | 0.090 |
Why?
|
| Specialization | 1 | 2011 | 23 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 327 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2015 | 1254 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2010 | 26 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 717 | 0.090 |
Why?
|
| Depression | 1 | 2015 | 504 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 755 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 5 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 245 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2011 | 241 | 0.080 |
Why?
|
| Phenotype | 2 | 2020 | 151 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 60 | 0.080 |
Why?
|
| Telephone | 3 | 2017 | 161 | 0.080 |
Why?
|
| Health Behavior | 2 | 2012 | 360 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2012 | 1287 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2009 | 165 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2007 | 10 | 0.070 |
Why?
|
| Sigmoidoscopy | 3 | 2013 | 65 | 0.070 |
Why?
|
| Pregnancy | 2 | 2023 | 1535 | 0.070 |
Why?
|
| Prolactin | 1 | 2007 | 4 | 0.070 |
Why?
|
| Medicare | 2 | 2017 | 199 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 561 | 0.060 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2017 | 227 | 0.060 |
Why?
|
| Texas | 1 | 2025 | 35 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 38 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2004 | 5 | 0.060 |
Why?
|
| Androgens | 1 | 2004 | 13 | 0.060 |
Why?
|
| Testosterone | 1 | 2004 | 23 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 78 | 0.060 |
Why?
|
| Parity | 1 | 2004 | 74 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2004 | 64 | 0.060 |
Why?
|
| Aromatase | 1 | 2004 | 8 | 0.060 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2004 | 5 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 6 | 0.060 |
Why?
|
| Age Distribution | 1 | 2004 | 246 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2004 | 27 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 63 | 0.050 |
Why?
|
| Office Visits | 2 | 2016 | 77 | 0.050 |
Why?
|
| Obesity | 2 | 2007 | 841 | 0.050 |
Why?
|
| Papanicolaou Test | 1 | 2022 | 37 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 75 | 0.050 |
Why?
|
| California | 2 | 2019 | 2327 | 0.050 |
Why?
|
| Self Report | 2 | 2013 | 252 | 0.050 |
Why?
|
| Body Mass Index | 4 | 2007 | 970 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 15 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2020 | 3 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 286 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 41 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 305 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 35 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 131 | 0.040 |
Why?
|
| Financial Support | 1 | 2019 | 5 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 75 | 0.040 |
Why?
|
| Demography | 1 | 2019 | 100 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 78 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 2 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 58 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2019 | 159 | 0.040 |
Why?
|
| Sulfonylurea Compounds | 1 | 2017 | 25 | 0.040 |
Why?
|
| Metformin | 1 | 2017 | 58 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 213 | 0.030 |
Why?
|
| Aftercare | 1 | 2016 | 48 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 639 | 0.030 |
Why?
|
| Idaho | 1 | 2013 | 24 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 74 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2012 | 33 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2012 | 33 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2014 | 248 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 296 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 159 | 0.020 |
Why?
|
| Nursing Care | 1 | 2010 | 4 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2010 | 11 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 29 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 44 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2010 | 12 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2012 | 301 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 377 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 252 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 416 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2007 | 21 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2007 | 166 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 4 | 0.010 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2004 | 1 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 381 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 85 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 227 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 226 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 211 | 0.010 |
Why?
|